- $17.26bn
- $19.45bn
- $2.86bn
U.S. STOCKS ON THE MOVE-Domino's Pizza, Eli Lilly, Revvity
Revvity rises after quarterly profit and sales beat estimates
Revvity beats quarterly estimates on steady demand for medical equipment
Brief: Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports (updated)
Brief: Revvity Files For Mixed Shelf Offering, Size Not Disclosed- SEC Filing
Brief: Revvity Wins Permanent Injunction Enforcing Agreements With Cloud Software Group
U.S. STOCKS ON THE MOVE-Charter Communications ,Eastman Chemical, Piper Sandler
U.S. STOCKS ON THE MOVE-Apple, Franklin Resources, Charter Communications
Revvity falls on forecasting 2025 revenue, profit below estimates
Revvity Inc reports results for the quarter ended December 31 - Earnings Summary
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
Brief: Revvity Q4 Adjusted EPS Continuing Operations USD 1.42
Brief: Revvity, Element Biosciences Collaborate To Advance Sequencing-Based Ivd Neonatal Testing
Brief: Revvity Announces FDA Clearance For First Automated Free Testosterone Test
Brief: Revvity Inc Enters Into Credit Agreement
U.S. RESEARCH ROUNDUP-Hershey, Paychex, Revvity
Brief: Scale Biosciences And Revvity's Biolegend Launch First-Of-Its-Kind Solution For High Parameter Protein Profiling Of Single Cells
Brief: Revvity Majority Of Applied Genomics Unit To Be Integrated Into Life Sciences Solutions Unit